Pioneer of antisense-oligonucleotide drugs, selling Tryngolza and Wainua and earning royalties on partnered medicines.
Pioneer of antisense-oligonucleotide drugs, selling Tryngolza and Wainua and earning royalties on partnered medicines.
Partners have long paid it upfront licence fees, milestone payments and royalties, which funded the business until its own medicines launched. It now sells Tryngolza itself and shares Wainua with AstraZeneca, so product sales are only starting to become a main income line.
Moat: narrow (IP / patents, process know-how). Deep antisense-chemistry patent estate and decades of manufacturing know-how license out to multiple partners.
Headquarters: Carlsbad, California, United States · Founded: 1989 · Employees: 1,402
Size Ionis Pharmaceuticals (IONS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $4.56B, the 1242nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $27.39 on 18 Nov 2026.
Performance Over six months the shares fell 63.5%, against +10.4% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue fell 0.8% over the last twelve months (peer median +12.0%); the operating margin is -58.9% (peer median 15.8%).
Valuation It trades at 5.0× enterprise value to sales against a peer median of 4.5× (8th most expensive of 18).
Capital Return on invested capital runs 72.1 points below its cost of capital (6.7% WACC).
Credit Ionis Pharmaceuticals has 2 bonds outstanding ($1.34B).
Short interest Short interest is 12.7% of the free float (30 Oct 2026).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $960M | $944M | $705M | $788M | $587M |
| Revenue growth | — | +34% | -10% | +34% | — |
| Gross profit | $916M | $915M | $672M | $756M | $551M |
| EBITDA | -$535M | -$359M | -$453M | -$331M | -$388M |
| Net income | -$546M | -$381M | -$454M | -$366M | -$270M |
| Free cash flow | -$616M | -$320M | -$546M | -$331M | -$290M |
| Capital expenditure | $78.4M | $57.1M | $50.3M | $28.0M | $20.1M |
| Total debt | $2.17B | $2.61B | $1.96B | $1.97B | $1.37B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals IONS | $4.56B | -64% | -1% | -59% | 5.0× | n/a |
| Alnylam Pharmaceuticals ALNY | $20.0B | -50% | +56% | 20% | 3.9× | 0.5% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 3.3× | -4.3% |
| Biogen BIIB | $37.2B | +34% | +2% | 17% | 4.4× | 10.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IONS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -39.7% | +0.7% | lowest of 21 |
| 6-month return | -63.5% | +10.4% | lowest of 21 |
| Distance from 52-week high | -68.4% | -29.4% | lowest of 21 |
| Revenue growth (TTM) | -0.8% | +12.0% | 4th lowest of 18 |
| Operating margin | -58.9% | 15.8% | lowest of 18 |
| EV / Sales | 5.0× | 4.5× | 8th most expensive of 18 |
| ROIC minus cost of capital | -72.1 pp | +4.9 pp | lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | 5.0× | n/a | n/a |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | Hong Kong | $4.48B | -23% | +6% | 3% | 0.6× | 1.3% | +4.0% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 4.5× | 15.9% | +12.7% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 6.5× | 23.8% | +13.8% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 3.2× | -9.9% | +0.3% |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 16.6× | 7.9% | +46.5% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.79B | +10% | +12% | 33% | 10.2× | 26.4% | +5.5% |
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 7.6× | 17.3% | +19.9% |
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $4.31B | -24% | +14% | 11% | 5.8× | 12.4% | +9.7% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 1.6× | -8.8% | +3.0% |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 2.2× | 1.7% | +6.2% |
| Santen Pharmaceutical 4536.T | Japan | $4.14B | +10% | +2% | 16% | 2.0× | -5.0% | +3.2% |
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 4.6× | 16.5% | +12.2% |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 3.1× | 6.6% | +35.4% |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 6.8× | -4.4% | +93.6% |
| Yuhan 000100.KS | South Korea | $4.11B | -10% | +8% | 6% | 2.3× | n/a | n/a |
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 7.8× | 5.0% | +192.5% |
| Definium Therapeutics DFTX | United States | $3.99B | +40% | n/a | n/a | n/a | n/a | n/a |
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| HanmiPharm 128940.KS | South Korea | $3.95B | -2% | +14% | 16% | 3.3× | 4.7% | +7.5% |
Ionis Pharmaceuticals has 2 bonds outstanding with $1.34B face value.